Compare Adaptive Biotechnologies Corp (ADPT) vs Axon Enterprise Inc (AXON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Axon Enterprise Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Axon Enterprise Inc trades at $602.49 (market cap $51.62B). The key difference: Axon Enterprise Inc is far larger — about 15.5× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | AXON | |
|---|---|---|
Market Cap | $3.33B | $51.62B |
Sector | Health | Technology |
52-Week High | $22.37 | $870.97 |
52-Week Low | $10.24 | $345.94 |
Enterprise Value | $3.19B | $52.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Axon Enterprise (AXON) trades at $622.20, up 4.21% today, with strong technical momentum as it crosses above key moving averages. The stock shows robust revenue growth, reaching $2.78 billion in 2025, though valuation ratios like a P/E of 250.95 appear elevated. Recent news highlights FAA drone defense approvals and CEO focus on non-lethal public safety technology, driving positive sentiment.
Outlook remains positive with an 80.95% analyst buy rating and $661.50 consensus price target, but risks include high valuation sensitivity and mixed earnings beats. Growth in software services and international expansion offer upside, while cash flow volatility and competitive pressures require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →
